Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Arcus Biosciences in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($3.93) per share for the year. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. During the same quarter last year, the company earned ($0.05) earnings per share. The firm's revenue for the quarter was down 80.7% on a year-over-year basis.
A number of other analysts have also weighed in on the company. Barclays cut their price objective on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Bank of America cut their price objective on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. The Goldman Sachs Group dropped their target price on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the company from $18.00 to $24.00 in a report on Wednesday, February 26th. Finally, Morgan Stanley dropped their target price on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Arcus Biosciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.13.
Check Out Our Latest Stock Analysis on RCUS
Arcus Biosciences Stock Down 9.3%
Shares of Arcus Biosciences stock traded down $0.94 during trading hours on Tuesday, reaching $9.09. 1,802,695 shares of the company were exchanged, compared to its average volume of 873,562. Arcus Biosciences has a 1 year low of $6.50 and a 1 year high of $18.98. The stock's fifty day moving average is $8.55 and its 200 day moving average is $11.34. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The firm has a market cap of $961.97 million, a PE ratio of -2.88 and a beta of 0.83.
Institutional Trading of Arcus Biosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in RCUS. Gilead Sciences Inc. purchased a new position in shares of Arcus Biosciences in the 4th quarter valued at approximately $447,610,000. Barclays PLC lifted its position in shares of Arcus Biosciences by 49.0% during the 3rd quarter. Barclays PLC now owns 118,693 shares of the company's stock valued at $1,816,000 after acquiring an additional 39,015 shares during the period. Norges Bank purchased a new position in shares of Arcus Biosciences during the 4th quarter worth approximately $507,000. Raymond James Financial Inc. purchased a new position in shares of Arcus Biosciences during the 4th quarter worth approximately $531,000. Finally, US Bancorp DE increased its stake in shares of Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company's stock worth $103,000 after purchasing an additional 6,615 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.
About Arcus Biosciences
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Read More
Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
